Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
STK4
REST API REST API
Homo sapiens
STK4 is differentially expressed in 290 experiments: 106 organism parts: bone marrow, lung, ... (104 more);, 235 disease states: normal, breast carcinoma, ... (233 more);, 108 cell types 366 cell lines 39 compound treatments and 82 other conditions.
Synonyms KRS2, MST1, YSK3
Orthologs ENSCING00000009234 (Ciona intestinalis)   Stk4 (Mus musculus)   STK4 (Gallus gallus)   KIC1 (Saccharomyces cerevisiae)   Stk4 (Rattus norvegicus)   STK4_BOVIN (Bos taurus)   hpo (Drosophila melanogaster)   stk4 (Xenopus laevis)   STK4 (Canis familiaris)   (Compare orthologs)
InterPro Term SARAH, Prot_kinase_cat_dom, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom, SARAH_domain
Gene Ontology Term protein binding, cytoplasm, negative regulation of cell proliferation, peptidyl-serine phosphorylation, protein tyrosine kinase activity, cell morphogenesis, positive regulation of apoptosis, negative regulation of organ growth, transcription factor binding, identical protein binding, ATP binding, induction of apoptosis, magnesium ion binding, protein dimerization activity, transferase activity, transferring phosphorus-containing groups, nucleus, nucleotide binding, protein serine/threonine kinase activity, protein homodimerization activity, signal transduction, protein kinase activity, central nervous system development, intracellular protein kinase cascade, neural tube formation, keratinocyte differentiation, cell differentiation involved in embryonic placenta development, patterning of blood vessels, hippo signaling cascade, negative regulation of canonical Wnt receptor signaling pathway, protein serine/threonine kinase activator activity, primitive hemopoiesis, protein autophosphorylation, endocardium development, protein phosphorylation, positive regulation of protein serine/threonine kinase activity
UniProt Accession Q13043, Q9BS84, F5H5B4
Search EB-eye ENSG00000101109
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MTAB-25, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (38 experiments)

Factor Value U/D Experiments
HepG2
3
E-MTAB-37, E-GEOD-21154, E-GEOD-7307
MCF-7
3
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639
A549
2
E-GEOD-6013, E-GEOD-3202
MCF-10A
2
E-GEOD-14990, E-TABM-420
MOLT4
2
E-MTAB-62, E-MTAB-37
BT474
1
2
E-MEXP-440, E-MTAB-62, E-MTAB-37
360 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-21909, E-GEOD-21750, ... (49 experiments)

Factor Value U/D Experiments
CD14+ monocyte
2
E-TABM-145, E-AFMX-5
CD19+ B cells (neg. sel.)
2
E-TABM-145, E-AFMX-5
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-26672
mononuclear
2
E-GEOD-13987, E-GEOD-26672
CD8+ T cell
1
2
E-TABM-145, E-AFMX-5, E-GEOD-19069
102 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-2280, E-GEOD-16363, E-MTAB-62, ... (58 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-GEOD-4290, E-MTAB-37, E-GEOD-4412
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
adenocarcinoma
2
E-MTAB-37, E-MTAB-62
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
colon carcinoma
2
E-MTAB-62, E-GEOD-3726
229 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-6907, E-GEOD-5824, E-GEOD-5099, ... (23 experiments)

Factor Value U/D Experiments
none
4
6
E-MEXP-1601, E-GEOD-5824, E-MEXP-1958, E-GEOD-2803, E-MEXP-1230, ... (10 experiments)
glutamine
2
E-MEXP-1335, E-MEXP-941
granulocyte-colony stimulating factor
1
E-GEOD-7400
Cxcl12
1
1
E-GEOD-7307
control - keratinocyte growth factor
1
E-GEOD-7216
mercaptopurine, methotrexate
1
E-GEOD-412
33 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1563, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, E-MEXP-2283, ... (6 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-MEXP-2280, E-TABM-147, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847, ... (6 experiments)

Genotype
studied in E-TABM-763, E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, E-GEOD-2292, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-6432, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-12773, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-5764, E-MEXP-2069, E-TABM-15, ... (34 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, ... (7 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Qrt pcr ereg dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, E-MEXP-1857, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

Sex
studied in E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290, E-GEOD-6532, E-GEOD-4922

Tumor size
studied in E-GEOD-6532

Processing time: 0.349 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM